Original Article

Experience with CellaVision DM96 for peripheral blood differentials in a large multi-center academic hospital system

Marian A. Rollins-Raval, Jay S. Raval, Lydia Contis

Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

E-mail: *Lydia Contis - contislc@upmc.edu *Corresponding author

Received: 26 February 12 Accepted: 31 May 12 Published: 25 August 12

This article may be cited as:

Rollins-Raval MA, Raval JS, Contis L. Experience with CellaVision DM96 for peripheral blood differentials in a large multi-center academic hospital system. J Pathol Inform 2012;3:29. Available FREE in open access from: http://www.jpathinformatics.org/text.asp?2012/3/1/29/100154

Copyright: © 2012 Rollins-Raval MA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Context and Aims: Rapid, accurate peripheral blood differentials are essential to maintain standards of patient care. CellaVision DM96 (CellaVision AB, Lund, Sweden) (CV) is an automated digital morphology and informatics system used to locate, pre-classify, store and transmit images of platelets, red and white blood cells to a trained technologist who confirms or edits CV cell classification. We assessed our experience with CV by evaluating sensitivity, specificity, positive predictive value and negative predictive value for CV in three different patient populations. Materials and Methods: We analyzed classification accuracy of CV for white blood cells, erythroblasts, platelets and artefacts over six months for three different university hospitals using CV. Results: CV classified 211,218 events for the adult cancer center; 51,699 events for the adult general hospital; and 8,009 events for the children's hospital with accuracy of CV being 93%, 87.3% and 95.4% respectively. Sensitivity and positive predictive value were <80% for immature granulocytes (band neutrophil, promyelocyte, myelocyte and metamyelocytes) (differences usually within one stage of maturation). Cell types comprising a lower frequency of the total events, including blasts, showed lower accuracy at some sites. Conclusions: The reduced immature granulocyte classification accuracy may be due in part to the subjectivity in classification of these cells, length of experience with the system and individual expertise of the technologist. Cells with low sensitivity and positive predictive value comprised a minority of the cells and should not significantly affect the technologist re-classification time. CV serves as a clinically useful instrument in performance of peripheral blood differentials.



Key words: Accuracy, CellaVision, image analysis, peripheral blood

BACKGROUND

Our center is a major university hospital system comprised of multiple hospital sites. The adult Cancer Center serves as the primary diagnostic and treatment facility for the majority of adult hematology/oncology inpatients and outpatients. The major adult general hospital houses most surgical, trauma, transplant and medical subspecialties of the system. The children's hospital provides a broad range of medical, oncologic and surgical services to children in the area. The need for rapid and accurate peripheral blood differentials is essential to maintain standards of patient care and safety in these settings. CellaVision DM96 (CellaVision AB, Lund, Sweden; distributed by Beckman Coulter, Inc., Brea, CA, USA and Sysmex Corporation, Kobe, Japan) (hereafter termed CV) is an automated digital morphology and informatics system used to locate, pre-classify, store, and transmit platelet, red blood cell, and white blood cell images to a trained technologist who confirms or edits CV cell classification. Detailed descriptions of the CV image analysis system have been previously given;^[1-3] briefly, CV initially scans a Romanowsky-stained peripheral blood smear at 1000× magnification in the "zone of morphology" as defined by the relative density of the cells. It then takes digital images of each cell representing a possible white blood cell (WBC). Artificial neural network-based software is used to analyze the cells by comparing the acquired digital images to those in a reference library provided by the manufacturer. Cells are then pre-classified into 18 categories, including leukocytes (segmented neutrophils, band neutrophils, eosinophils, basophils, lymphocytes, monocytes, blasts, promyelocytes, myelocytes, metamyelocytes, variant lymphocytes, plasma cells and unidentified) and non-leukocytes (smudge cells, artifacts, giant platelets, nucleated red blood cells, platelet clumps). After analysis by CV, a technologist reviews these images and either agrees with the CV pre-classification, leaving the cells in the pre-classified categories, or disagrees with the instrument's determination and moves the cells into different categories. Once the technologist has reviewed all of the images and the differential is approved, it is subsequently released to the laboratory information system. Previous studies have shown that CV has a reproducibility of less than 2.5 standard deviations for all cell classes.^[3] and that the overall time for the differential remains the same or decreases with the use of CV. The rate appears to vary by technologist, with more experienced technologists performing manual differential rates similar to those of CV differential rates; for less experienced technologists the CV differential rate is less than the manual differential rate.^[1,4]

Timing studies previously performed at our institution demonstrated that a manual differential averaged 5.8 minutes, while the CV differential averaged 3.1 minutes. This translated to a reduction of 2.7 minutes per slide.^[5] Theoretically, CV efficiency would increase as the need to edit classification (i.e. technologist time) decreases. The goal of the present study was to define the accuracy of CV peripheral blood differential as compared to the technologist review of the CV differential at three unique hospitals in our institution's medical system.

MATERIALS AND METHODS

Per laboratory standard operating procedures, peripheral blood specimens "flagged" by the automated cell counter for microscopic review were routed to CV for analysis. Separate manual differentials were not performed on these specimens. Peripheral blood smears were performed using premium glass slides with a clipped corner, which were Wright-Giemsa stained on the Beckman-Coulter LH750 slide maker stainer (Beckman Coulter, Inc., Brea, CA, USA) according to standard protocols at three unique hospitals in our institution's medical system. Each slide was then analyzed at 1000x under oil by CV, which acquired images of and classified each of the following cell types: promyelocyte, myelocyte, metamyelocyte, band neutrophil, segmented neutrophil, eosinophil, basophil, monocyte, lymphocyte, variant lymphocyte, plasma cell, blast cell, smudge cell, erythroblast (nRBC), giant platelet, and artefact. For each slide, CV analyzed 110 events and at least 100 leukocytes were ultimately counted; this allowed for non-leukocyte events to be removed if necessary.

A medical technologist or medical laboratory technician (the majority of whom have over 20 years of experience at our institution) then visually reviewed the CV image differential and reclassified cells as necessary; their interpretation served as the gold standard, or true values. When indicated, less-experience technologists operating CV were supervised by their senior counterparts. The final results were subsequently released to the laboratory information system. As these technologist reviews of CV images were part of the clinical service's standard operating procedure, no intra-person or inter-person validation was performed for the differentials.

Using CV's Database Query Tool, Version 4.2 (CellaVision AB, Lund, Sweden), we analyzed the classification accuracy of CV at each site for white blood cells, erythroblasts, platelets, and artefacts over a six month period. We assessed our experience with CV by evaluating the sensitivity and specificity of CV initial classification as well as the positive and negative predictive values of a cell type identified by CV. All analyses and statistical calculations were performed utilizing GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA).

RESULTS

CV classified 211,218 events for the adult cancer center, 51,699 events for the adult general hospital; and 8,009 events for the children's hospital. For all events, the accuracy of CV was 93% for adult cancer center; 87.3% for adult general hospital; and 95.4% for the children's hospital. Tables 1-3 demonstrate the event collection and classification data and Tables 4-6 demonstrate all calculations and analyzes for all of the event collection and classification data for the adult cancer center, adult general hospital and children's hospitals respectively.

At the adult cancer center, positive predictive values and sensitivities for CV were both >80% for segmented neutrophils, eosinophils, lymphocytes, monocytes, giant platelets, smudge cells, and artefacts. Positive predictive

Cell 1	ype									Techno	logist	verifie	d differ	ential								· c
		Band neu- tro- phil	Seg- ment- ed neu- tro- phil	Eo- sino- phil	Ba- so- phil	Lym- pho- cyte	Mono- cyte	Pro- my- elo- cyte	My- elo- cyte	Meta- my- elo- cyte	Blast	Vari- ant lym- pho- cyte	Plas- I ma s cell	-arge gran- ular Jym- pho- cyte	er –	Eryth- ro- blast	Giant plate- let	Plate- let ag- ga- ga- tion	Mega- karyo- cyte	Smudge cell	Arte- fact	lavi- sion differ- ential (To- tal)
Cel-	Unidentified	640	770	52	28	46	192	0	72	338	3	4	0	0	-	-	7	-	0	132	8	2350
lavi-	Band neutrophil	6756	4071	35	61	0	4	0	6	134	0	0	0	0	0	0	_	0	0	104	15	11148
sion initial	Segmented neutrophil	1388	105517	64	82	S	7	0	9	23	0	7	0	0	0	7	0	0	0	284	59	107439
-IID fer	Eosinophil	7	266	2832	_	_	0	0	0	2	_	0	0	0	0	9	0	_	0	268	42	3427
ential	Basophil	17	66	m	618	45	24	4	17	33	=	2	0	0	0	2	_	0	0	312	77	1265
	Lymphocyte	2	22	0	6	21789	46	0	2	7	130	8	0	0	_	7	20	0	0	80	52	22248
	Monocyte	43	82	0	_	=	10534	0	13	31	61	22	0	0	0	0	0	0	0	36	9	10798
	Promyelocyte	m	_	0	0	0	93	43	146	25	4	7	0	0	0	0	0	0	0	6	m	329
	Myelocyte	33	25	m	_	2	4	_	585	283	_	2	0	0	0	m	0	0	0	24	=	988
	Metamyelocyte	157	139	œ	_	_	13	0	16	842	0	_	0	0	0	_	0	_	0	0	4	1194
	Blast	m	15	0	9	67	66	_	4	_	426	78	0	0	<u>2</u>	0	2	_	0	=	=	738
	Variant	0	4	_	0	206	257	0	m	с	42	908	0	0	2	0	0	0	0	33	15	1474
	lymphocyte																					
	Plasma cell	0	0	0	0	108	37	0	_	0	7	206	26	0	0	13	0	0	0	7	12	412
	Large granular Iymphocyte	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Erythroblast	m	125	0	0	0	_	0	0	_	_	0	0	_	0	2666	86	0	0	136	410	3437
	Giant platelet	0	9	_	_	0	0	0	0	0	0	0	0	0	0	_	8049	61	9	170	184	8439
	Platelet	0	0	0	0	0	0	0	0	0	0	0	0	0	0	_	78	286	0	72	125	572
	aggregation																					
	Megakaryocyte	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Smudge cell	œ	114	4	7	œ	4	0	7	9	œ	ъ	0	_	0	_	_	ъ	0	17473	24	17666
	Artefact	0	20	2	_	0	0	0	0	_	0	0	0	0	0	9	0	39	0	71	17153	17294
Techni differe	ologist verified ntial (Total)	0906	111286	3005	770	22289	11325	49	876	1730	658	I 353	26	2	17	2710	8240	353	6	19232	18221	211218**
Highlig	hted cells repres	sent cell	s correct	tly pre	classifi	ed by th	e CellaV	ision*	k includ	les ten c	cells no	ot classi	ified by	the tec	hnolog	ist (7 er	ythrobla	ists, 2 gi	ant platel	lets, l arte	fact)	

Table 1: Adult cancer center event collection and classification data

Cell type							۳	schnol	ogist Ve	rified	Differe	ential							Cel-
	Band neu- tro- phil	Seg- ment- ed	Eo- sino- phil	Ba- so- phil	Lym- pho- cyte	Mono- cyte	Pro- my- cyte	My- elo- cyte	Meta- my- elo- cyte	Blast	Vari- ant Iym- pho-	Plas- ma cell	oth- er	Eryth- ro- blast	Giant plate- let	Plate- let aggre- gates	Smudge cell	Ar- te- fact	lavision initial differ- ential
	-	trophil					•		•		cyte)			(IOLAI)
Cellavision Unidentified	36	16	-	9	25	40	-	27	27	0	6	0	0	=	0	0	17	48	339
differential Band neutrophil	3151	1227	0	_	6	15	0	2	25	0	0	0	0	_	0	0	01	4	4458
Segmented neutrophil	829	24997	0	4	_	7	0	_	S	0	0	0	0	m	0	0	36	36	25914
Eosinophil	25	315	823	m	0	_	0	0	m	0	0	0	0	2	0	0	34	50	1256
Basophil	2	8	_	4	_	2	0	0	0	0	0	0	0	0	0	0	12	49	227
Lymphocyte	_	2	0	0	3804	61	0	2	S	0	47	0	0	6	_	0	6	65	3964
Monocyte	116	55	0	0	6	0061	0	7	15	0	7	0	0	0	0	0	15	8	2142
Promyelocyte	2	5	0	0	0	62	16	œ	S	0	0	0	_	0	0	0	0	16	125
Myelocyte	ъ	4	0	0	_	9	0	48	12	0	_	0	0	0	0	0	m	m	83
Metamyelocyte	54	17	0	0	m	47	_	=	154	_	0	0	0	0	0	0	S	12	305
Blast	0	m	0	_	_	4	0	0	0	_	17	0	_	0	0	0	m	8	49
Variant	0	0	0	0	22	5	0	0	0	0	31	0	0	0	0	0	2	9	99
lymphocyte																			
Plasma cell	0	0	0	0	20	7	0	0	0	0	01	0	0	_	0	0	_	_	40
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Erythroblast	0	12	_	0	01	0	0	0	0	0	0	0	0	476	_	0	4	76	590
Giant platelet	2	4	0	0	_	_	0	0	0	0	0	0	0	_	832	_	01	666	1518
Platelet	_	m	0	0	_	0	0	0	0	0	0	0	0	0	91	103	=	129	264
aggregates																			
Smudge cell	4	24	4	m	4	_	0	0	0	0	0	0	0	_	0	0	1802	1499	3342
Artefact	4	149	_	9	01	_	_	_	0	0	2	0	0	5	0	0	_	6836	7017
Technologist verified differential	4232	26926	831	165	3922	2113	61	011	251	7	124	0	7	510	850	104	1995	9542	51699**
Highlighted cells represent c technologist	ells corre	ectly pre	classifie	d by th	e CellaV	ision **ir	Icludes	I cell o	classified	as a b	asophil	by Cell	a Vision	was plac	ed in pla	telet mor	rphology ca	tegory	bу

Table 3: Ch	ildren's hospit	al event	t collect	tion an	d clas	sificati	on data	~											
Cell type								Techr	nologist	t verifie	d differ	ential							Cel-
		Band neu- trophil	Seg- ment- ed neu- trophil	Eo- phil	Ba- so- phil	Lym- pho- cyte	Mono- cyte	Pro- my- elo- cyte	My- elo- cyte	Meta- my- elo- cyte	Blast	Vari- ant lym- pho- cyte	Plas- ma cell	Eryth- roblast	Giant plate- let	Plate- let aggre- gation	Smudge cell	Ar- te- fact	lavi- sion nitial fiffer- ential (To- tal)
Cellavision	Unidentified	16	13	7	m	ъ	6	0	-	4	4	4	0	0	0	0	01	7	73
initial	Band neutrophil	167	16	4	_	_	0	0	0	0	0	0	0	0	0	0	0	0	189
differential	Segmented neutrophil	61	2607	4	0	0	7	0	0	0	0	0	0	0	0	0	7	0	2681
	Eosinophil	_	17	901	0	_	0	0	0	0	0	0	0	0	0	0	œ	0	133
	Basophil	0	m	0	25	7	0	0	0	0	_	0	0	0	0	0	21	6	99
	Lymphocyte	0	0	0	0	1505	0	0	0	0	5	_	0	0	0	0	2	0	1513
	Monocyte	0	0	0	0	0	448	0	0	0	_	4	0	0	0	0	_	0	454
	Promyelocyte	0	0	0	0	0	_	9	_	0	0	_	0	0	_	0	0	0	0
	Myelocyte	0	0	0	_	0	0	0	6	0	0	0	0	0	0	0	0	_	=
	Metamyelocyte	0	0	0	0	0	4	0	0	4	0	0	0	0	0	0	0	0	8
	Blast	0	_	0	0	5	_	0	0	0	124	0	0	0	0	0	0	0	131
	Variant	0	0	0	0	_	_	0	0	0	0	86	0	0	0	0	0	0	88
·	lymphocyte																		
	Plasma cell	0	0	0	0	0	_	0	0	0	_	_	_	0	0	0	0	_	15
	Erythroblast	0	ъ	0	0	_	0	0	0	0	0	0	0	112	0	0	_	61	138
	Giant platelet	0	m	0	0	0	_	0	0	0	0	0	0	0	358	0	7	5	374
	Platelet	0	9	0	0	0	0	0	0	0	0	0	0	0	2	4	17	0	29
	aggregation																		
-	Smudge cell	0	m	_	0	0	0	0	0	0	_	0	0	0	0	0	1070	0	1075
	Artefact	0	6	_	_	0	0	0	0	0	0	0	0	0	0	0	0	0001	101
Technologist differential	verified	245	2683	811	31	1536	468	6	=	8	137	76	_	112	361	4	1144	1037	8009
Highlighted ce	lls represent cells	correctly	y preclass	ified by	the Cel	lavision													

Table	4:	Adult	cancer	center	calculations	and	analysis
-------	----	-------	--------	--------	--------------	-----	----------

Cell type	Proportion of total events* (%)	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
Unidentified	1.11	N/A	N/A	N/A	N/A
Band neutrophil	4.29	74.57	97.83	60.60	98.85
Segmented neutrophil	52.69	94.82	98.08	98.21	94.44
Eosinophil	1.42	94.24	99.71	82.64	99.92
Basophil	0.36	80.26	99.69	48.85	99.93
Lymphocyte	10.55	97.76	99.76	97.94	99.74
Monocyte	5.36	93.02	99.87	97.56	99.61
Promyelocyte	0.02	87.76	99.86	13.07	100.00
Myelocyte	0.41	66.78	99.81	59.21	99.86
Metamyelocyte	0.82	48.67	99.83	70.52	99.58
Blast	0.31	64.74	99.85	57.72	99.89
Variant lymphocyte	0.64	67.11	99.73	61.60	99.79
Plasma cell	0.01	100.00	99.82	6.31	100.00
Large granular lymphocyte	0.00	0.00	100.00	N/A	100.00
Other	0.01	0.00	100.00	N/A	99.99
Erythroblast	1.28	98.38	99.63	77.57	99.98
Giant platelet	3.90	97.68	99.81	95.38	99.91
Platelet aggregation	0.17	81.02	99.86	50.00	99.97
Megakaryocyte	0.00	0.00	100.00	N/A	100.00
Smudge cell	9.11	90.85	99.90	98.91	99.09
Artefact	8.63	94.14	99.93	99.18	99.45

*includes ten cells not classified by the technologist (7 erythroblasts, 2 giant platelets, I artefact)

Table 5: Adult general hospital calculations and analysis

Cell type	Proportion of total events* (%)	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
Unidentified	0.66	N/A	N/A	N/A	N/A
Band neutrophil	8.19	74.46	97.25	70.68	97.71
Segmented neutrophil	52.08	92.84	96.30	96.46	92.52
Eosinophil	1.61	99.04	99.15	65.53	99.98
Basophil	0.32	85.45	99.83	62.11	99.95
Lymphocyte	7.59	96.99	99.67	95.96	99.75
Monocyte	4.09	89.92	99.51	88.70	99.57
Promyelocyte	0.04	84.21	99.79	12.80	99.99
Myelocyte	0.21	43.64	99.93	57.83	99.88
Metamyelocyte	0.49	61.35	99.71	50.49	99.81
Blast	0.00	50.00	99.91	2.04	100.00
Variant lymphocyte	0.24	25.00	99.93	46.97	99.82
Plasma cell	0.00	N/A	99.92	0.00	100.00
Other	0.00	0.00	100.00	N/A	100.00
Erythroblast	0.99	93.33	99.78	80.68	99.93
Giant platelet	1.64	97.88	98.65	54.81	99.96
Platelet aggregation	0.20	99.04	99.69	39.02	100.00
Smudge cell	3.86	90.33	96.90	53.92	99.60
Artefact	18.46	71.64	99.57	97.42	93.94

*I cell classified as a basophil by CellaVision was placed in platelet morphology category by technologist

values and sensitivities were both <80% for immature granulocytes (band neutrophils, myelocytes, and metamyelocytes), variant lymphocytes, and blasts. The positive predictive values of CV for promyelocytes and

plasma cells were low (13.1% and 6.3%); however, the sensitivities of CV identifying these two cell types were quite high (87.8% and 100%). Negative predictive values and specificities for all cell types were all >94%.

Cell type	Proportion of total events (%)	Sensitivity (%)	Specificity (%)	Positive predictive value (%)	Negative predictive value (%)
Unidentified	0.91	N/A	N/A	N/A	N/A
Band neutrophil	3.06	68.16	99.72	88.36	99.00
Segmented neutrophil	33.50	97.17	98.61	97.24	98.57
Eosinophil	1.47	89.83	99.66	79.70	99.85
Basophil	0.39	80.65	99.49	37.88	99.92
Lymphocyte	19.18	97.98	99.88	99.47	99.52
Monocyte	5.84	95.73	99.92	98.68	99.74
Promyelocyte	0.07	100.00	99.95	60.00	100.00
Myelocyte	0.14	81.82	99.97	81.82	99.97
Metamyelocyte	0.22	77.78	99.95	77.78	99.95
Blast	1.71	90.51	99.91	94.66	99.83
Variant lymphocyte	1.21	88.66	99.97	97.73	99.86
Plasma cell	0.01	100.00	99.83	6.67	100.00
Erythroblast	1.40	100.00	99.67	81.16	100.00
Giant platelet	4.51	99.17	99.79	95.72	99.96
Platelet aggregation	0.05	100.00	99.69	13.79	100.00
Smudge cell	14.28	93.53	99.93	99.53	98.93
Artefact	12.95	96.43	99.84	98.91	99.47

 Table 6: Children's hospital calculations and analysis

At the adult general hospital, positive predictive values and sensitivities for CV were >80% for segmented neutrophils, lymphocytes, monocytes, and erythroblasts. Similar to the adult cancer center's, positive predictive values and sensitivities were both <80% for immature granulocytes (band neutrophils, myelocytes, metamyelocytes), variant lymphocytes, and blasts. The positive predictive values of CV for blasts and promyelocytes were low (2.0% and 12.8%, respectively). The sensitivity of CV for promyelocytes was 84.2%, however the 50.0% sensitivity for blasts was much lower. Negative predictive values and specificities for all cell types were all >92%.

At the children's hospital, positive predictive values and sensitivities for CV were >80% for segmented neutrophils, lymphocytes, monocytes, myelocytes, blasts, variant lymphocytes, erythroblasts, giant platelets, smudge cells, and artefacts. Unlike the other two sites, both positive predictive value and sensitivity was only <80% for metamyelocytes (and even then only 77.8% and 77.8%). The positive predictive values of CV for plasma cells and platelet aggregation were 6.7% and 13.8%. Sensitivities of CV for these two cell types were 100%. Negative predictive values and specificities for all cell types were all >98%.

DISCUSSION

In this analysis of CV utilization at three different hospitals with distinct patient populations in a large academic hospital system that has been using CV image differentials for 5 years, the overall accuracy of CV in classifying white blood cells is excellent. It has been previously noted that the overall percentage of cells correctly identified by CV was between 82% and 92%,^[1,3,6,7] and that specificity was >97% for all cell types;^[7] these findings are consistent with the results at all three of our sites. Previous studies have also shown that the pre-classification agreement of CV for identifying segmented neutrophils, lymphocytes, and monocytes was between 81.4% and 99% due to their presence in large amounts.^[1,6-8] This degree of accuracy was seen at our institution, as the positive predictive values and sensitivities of these three cell types in our analysis were all >89%. However, other cell types may be misclassified, perhaps due to either the low percentage of these cells in patient samples or to inter-individual morphologic variation. Cell types identified by CV with both low positive predictive values and sensitivities in our analysis comprised a minority of the cell types and should not significantly affect the technologist reclassification time. In analyzing the data, CV had difficulty in reliably identifying three specific cell types: immature granulocytes, plasma cells, and blasts.

Previous analysis of granulocyte precursors with CV have demonstrated less than optimal correlation with direct microscopy.^[2,7,9] As this was also true in our analysis, reduced immature granulocyte classification accuracy may be due in part to the subjectivity in classification of these cell types, length of experience with the CV system, and individual expertise of the technologist. However, differences identified by the technologist were generally within one stage of maturation.

For plasma cells, a low event cell type that had low positive predictive values by CV at all three sites, the definition in CV likely needs refinement. However, at the two sites that actually had plasma cells remaining in that category after reclassification by the technologist, those remaining were all placed there by CV (100% sensitivity). This is significantly greater than previously reported 25% sensitivity of CV for identifying cell categories that included plasma cells.^[1]

For blast identification in adult patients, the majority of events moved into this category by the technologist were from lymphocytes and lymphocyte variants, suggesting that the technologist identified lymphoblasts missed by CV. The events moved out went to lymphocytes, lymphocyte variants, monocytes, and artefacts, suggesting that CV overcalled some lymphoid forms as blasts as well as overcalled some monocytes and promonocytes as blasts. These are important but sometimes subtle distinctions that may be difficult to make even for an experienced hematopathologist. Interestingly, blast identification in the pediatric population had excellent positive predictive value and sensitivity (94.7% and 90.5%). This was an improvement over the findings of a previous CV study of pediatric WBC differentials that underestimated the percentage of malignant cells.^[10] While the specific reason for the more accurate identification of blasts in pediatric patients is not known, it may be due to the narrower range of atypical hematopoietic cells that can resemble blasts in children.

It should be noted that CV can simultaneously display all cells of the same class on the viewing panel. The ability to compare cells head-to-head in real time can be valuable in assisting the technologist in the task of correctly identifying a specific cell.

Other methods of cell analysis and characterization such as flow cytometric studies, either alone or in conjunction with either hematology analyzers or high speed image capture, may further assist in the correct identification of difficult-to-classify cells.^[11,12] However, algorithms of sequential analysis with CV followed by other analytic techniques have yet to be described.

The primary limitation of this study is the verification of CV differentials by different technologists. Cell types with poor positive predictive values and sensitivities warrant additional study as smaller group size or range, combined with limited technologist experience with CV technology as well as varying proficiencies, could have contributed to the lower identification accuracy by CV. However, in spite of having different technologists with varying levels of expertise and experiences with CV, overall accuracy of CV at all three labs remained high, thus demonstrating the positive assimilation of CV into the three different types of hematology laboratories. Correlation of CV results with specific disease diagnosis could not be performed in the current study due to de-identification of all data in the CV database prior to analysis. However, it would be interesting in future investigations to determine whether specific clinical conditions affect the ability of CV to accurately identify specific cell types.

Overall, CV serves as a clinically useful instrument in the performance of white blood cell differentials at our institution. Other potential benefits of CV include image storage of abnormal cells for review by pathologists or clinicians either on- or off-site, incorporation of images into patient electronic medical records and reports, and utilization as a teaching tool for technologists, pathology trainees, and clinicians. The potential for reduction of labor costs is an additional important consideration in the evaluation of this technology, especially in high volume laboratories which perform numerous manual differentials. As CV continues its role successfully in hematology laboratories and expands its reach beyond the pathology laboratory information systems, continued assessments will be required to ensure its accuracy and efficacy.

ACKNOWLEDGEMENTS

The authors would like to thank Betty Austin, MT (ASCP) at UPMC Presbyterian Hospital, Susan Waugaman, MT (ASCP) at UPMC-Shadyside Hospital, Marianne Riazzi, MLT (ASCP), MT at Children's Hospital of Pittsburgh of UPMC, and Emily Thompson, MT (ASCP), MSE at CellaVision.

REFERENCES

- Kratz A, Bengtsson HI, Casey JE, Keefe JM, Beatrice GH, Grzybek DY, et al. Performance evaluation of the CellaVision DM96 system: WBC differentials by automated digital image analysis supported by an artificial neural network. Am J Clin Pathol 2005;124:770-81.
- Briggs C, Longair I, Slavik M, Thwaite K, Mills R, Thavaraja V, et al. Can automated blood film analysis replace the manual differential? An evaluation of the CellaVision DM96 automated image analysis system. Int J Lab Hematol 2009;31:48-60.
- Ceelie H, Dinkelaar RB, van Gelder W. Examination of peripheral blood films using automated microscopy; evaluation of Diffmaster Octavia and Cellavision DM96. J Clin Pathol 2007;60:72-9.
- Cornet E, Perol JP, Troussard X. Performance evaluation and relevance of the CellaVision DM96 system in routine analysis and in patients with malignant hematological diseases. Int J Lab Hematol 2008;30:536-42.
- Contis L, Williams C. Evaluation of an automated digital cell morphology and informatics system for use in a large hematology oncology center. In: International Society for Laboratory Hematology. Amsterdam; 2006.
- Seeto M, Ledesma A, Duff J, Houliston P, Lupscha M, Kabral A. Evaluation of the CellaVision DM96 system: Familiarisation study in a large laboratory setting. In: International Society for Laboratory Hematology. Sydney; 2008.
- Francois M, Francoise T, Gothot A. A performance evaluation of the CellaVision Dm96 for automated routine leucocyte differential in an academic hospital. In: International Society for Laboratory Hematology. Brighton; 2010.
- Brusselmans C. Cellular analysis by digital microscopy. In: International Society for Laboratory Hematology. Las Vegas; 2009.
- Merino A, Brugues R, Garcia R, Kinder M, Bedini JL, Escolar G. Comparative study of peripheral blood morphology by conventional microscopy and Cellavision DM96 in hematological and non hematological diseases. In: International Society for Laboratory Hematology. New Orleans; 2011.
- Billard M, Lainey E, Armoogum P, Alberti C, Fenneteau O, Da Costa L. Evaluation of the CellaVision DM automated microscope in pediatrics. Int J Lab Hematol 2010;32:530-8.

- Mirabelli P, Scalia G, Pascariello C, D'Alessio F, Mariotti E, Di Noto R, et al. ImageStream promyelocytic leukemia protein immunolocalization: In search of promyelocytic leukemia cells. Cytometry A 2012;81:232-7.
- 12. Kleine TO, Nebe CT, Lower C, Geilenkeuser WJ, Dorn-Beineke A.

Cell analysis in cerebrospinal fluid (CSF) using Sysmex(R) hematology analyzers XT-4000i and XE-5000: Evaluation with CSF controls of the Joint German Society for Clinical Chemistry and Laboratory Medicine (DGKL). Cytometry A 2012;81:255-64.